Linked Life Data

12221168

Source:http://linkedlifedata.com/resource/pubmed/id/12221168

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2002-9-10
pubmed:abstractText
Depression is a suspected side effect of treatment with interferon beta1a in MS. However, an association with depression has not been confirmed by rigorous studies. During the SPECTRIMS clinical trial of interferon beta1a (Rebif) in secondary progressive MS, depression ratings were obtained from 365 subjects treated either with interferon beta1a or with placebo. No significant differences between groups emerged during 36 months of follow-up. These data suggest that depression is not a side effect of interferon beta1a.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0028-3878
pubmed:author
pubmed:issnType
Print
pubmed:day
10
pubmed:volume
59
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
744-6
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
2002
pubmed:articleTitle
Interferon beta1a and depression in secondary progressive MS: data from the SPECTRIMS Trial.
pubmed:affiliation
Department of Community Health Sciences and Psychiatry, University of Calgary, Alberta, Canada. patten@ucalgary.ca
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study